Updated testing guidelines make more women eligible for herceptin, yet benefit uncertain
Wednesday, July 27, 2016 - 14:31
in Health & Medicine
Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study. Cancers that have an excess of HER2 protein or extra copies of the HER2 gene are called HER2-positive and can be treated with drugs like Herceptin that target HER2. HER2 stands for human epidermal growth factor receptor 2.